The US Food & Drug Administration (FDA) approval of aducanumab to treat Alzheimer’s disease has proved controversial, with dementia researchers hailing it as a major step forward while geriatricians have condemned it as premature and lacking sufficient evidence of benefit. Biogen’s US$56,000/year drug was granted accelerated approval based on surrogate endpoint of reduction of amyloid ...
Controversy rages over aducanumab approval for Alzheimer’s disease
By Michael Woodhead
9 Jun 2021